Piramal Pharma Ltd - 543635 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ajay G Piramal & Others Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Issue of Advertisement in newspapersin respect of certain matters relating to rights issue of equity shares of face value of Rs. 10 each ("Rights Issue") of the Company Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Meeting Updates
Intimation of the outcome of the meeting of the Committee of Directors (Rights Issue) of Piramal Pharma Limited held on August 22, 2023 Piramal Pharma rights issue: What should investors do?
The underlying stock is fairly priced and at a rights issue ratio of 5:46, the discount on additional shares is marginal Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference Call with Investors/Analysts Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference Call with Investors/Analysts Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Meeting Updates
Outcome of the meeting of the Committee of Directors (Rights Issue) of Piramal Pharma Limited held on August 4, 2023 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Conference Call on the financial results (Standalone and Consolidated) for the quarter ended 30th June, 2023